Tenon Medical, Inc.: Tenon Medical Reports Second Quarter 2026 Financial Results
Tenon Medical (NASDAQ:TNON) reported Q2 2026 revenue of $1.3M, up 127% year over year, and gross profit of $0.8M with 64% gross margin. Net loss was $4.1M ($12.35/share). The company received FDA 510(k) clearance for an updated Catamaran SI Joint Fusion System, closed a $4.2M public offering, and completed a 1-for-35 reverse split.
How this was made
The 30-second read
Why it matters
Traders can frame TNON’s near-term outlook around (1) improved gross margin and record case volume, (2) FDA 510(k) clearance for updated Catamaran instruments expected to reduce per-procedure costs, and (3) liquidity and capital structure risk from the $4.2M offering, low cash balance, and Sept 2026 convertible-note maturity.
Market read
This is a company-specific earnings and regulatory update with concrete financial metrics, FDA clearance details, and a post-quarter capital raise, which can drive both fundamental repricing and financing-related volatility.
What to watch
The reverse split (1-for-35) and Nasdaq minimum bid compliance effort can pressure sentiment, and the convertible notes mature on Sept 11, 2026, making near-term capital structure execution critical.
Background
Tenon Medical is a medical device company focused on sacro-pelvic disorders, reporting Q2 2026 results and providing updates on FDA clearance, procedure volume, financing, and Nasdaq compliance.
Ticker impact
Tenon Medical reported Q2 2026 revenue of $1.3M (+127% YoY) and gross margin of 64%, plus FDA 510(k) clearance for an updated Catamaran system.
Likely positive bias for TNON on margin and FDA clearance, but expect volatility tied to limited cash ($1.7M at June 30) and financing needs into September 2026.
The article provides multiple fresh, company-specific datapoints: Q2 financials, FDA 510(k) clearance details, record monthly case volume, a post-quarter $4.2M public offering, and a 1-for-35 reverse split with Nasdaq compliance efforts.
Market effects
Small-cap medical device peers may see read-across interest in sacro-pelvic/surgical implant procedure adoption and reusable-instrument cost economics.
Limited, primarily affects US small-cap biotech/medtech sentiment rather than broad regional flows.
Low, as the disclosures are US-focused (FDA 510(k), Nasdaq compliance, US offering).
Counterpoint
Despite strong YoY growth and margin expansion, TNON still posted a $4.1M quarterly net loss and ended Q2 with only $1.7M cash, so the equity story may be dominated by dilution and refinancing risk.
Key entities
- companyTenon Medical, Inc.
NASDAQ-listed medical device company reporting Q2 2026 results, FDA clearance, and financing updates.
- productCatamaran SI Joint Fusion System
Updated system received FDA 510(k) clearance, including instrument upgrades and a shift of some instruments from disposable to reusable.
- capital_structureConvertible notes
$5.2M convertible notes mature Sept 11, 2026 (extendable to Dec 11, 2026).
